Effectiveness of nutritional intervention to management Systemic Arterial Hypertension in Primary Health Care

Not Applicable

• Conditions: Hypertension; I- 10

• Registration Number: RBR-5hvgtky
• Lead Sponsor: niversidade Federal de Ouro Preto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-15
• Last Update Posted: 29 May 2023
• Study Completion: 2024-01-30

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Both sexes; over 20 years old

Exclusion Criteria

Volunteers with cardiovascular disease, angina, heart attack, heart failure, atherosclerosis, peripheral vascular disease, ischemic cerebrovascular disease, chronic liver, kidney or infectious diseases evaluated by medical history; 10% change in body weight two months prior to the study; use of anti-inflammatory drugs; women on exogenous ovarian hormone replacement, pregnancy or breastfeeding; people with special needs; Alzheimer's disease, dementia or life expectancy shorter than study duration; cognitive difficulties.

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluate the reduction in blood pressure values ??of PHC (Primary Health Care) users with SAH (Systemic Arterial Hypertension) in Ouro Preto, Minas Gerais, verified by the method of measuring blood pressure using the sphygmomanometer instrument at the beginning of the study and at the end of the study. Blood pressure is expected to decrease to values ??close to 120 mmHg for systolic pressure and 80 mmHg for diastolic pressure.

Secondary Outcome Measures

Name	Time	Method
It is expected to find a 5% reduction in the Framingham risk score for cardiovascular diseases when compared to the values ??measured at the beginning of the study. We will observe a reduction in the consumption of ultra-processed foods in the daily diet, when compared to the amount verified at the beginning of the study and at the end of the study. A reduction of CRP (C-reactive protein), IL-6 (interleukin 6) and CRP and microalbuminuria by 10% is expected when compared to the initial value, based on the difference between hyper and normotensive individuals for CRP.